Pennsylvania -- (MARKET WIRE) -- December 8, 2006 --
PuriCore's Greg Bosch wins 'Life Sciences CEO of the year' award
MALVERN, PENNSYLVANIA, and STAFFORD, UK, December 8, 2006 -- PuriCore plc
("PuriCore" or the "Company") (London Stock Exchange: PURI) today
announces that its CEO, Greg Bosch, has been awarded the 'Life Sciences
CEO of the Year' award at the annual Eastern Technology Council's ("ETC")
Enterprise Awards in Philadelphia.
Over the past 14 years, the ETC Awards have developed the reputation as
being one of the most prestigious honours for a company to win on the
East Coast of the United States.
Bosch was appointed CEO of PuriCore in November 2004 and has been
instrumental in the commercialisation of PuriCore's proprietary
technology, known as Sterilox. In June 2006, Greg led the Company
through a successful flotation on the London Stock Exchange, raising £30
million ($54.5 million).
Greg Bosch commented: "I am honoured to receive this award. It reflects
the hard work and dedication of the entire team at PuriCore as we
continue towards our vision to be a global leader in advancing human
health through the environmental control of pathogens."
FOR FURTHER INFORMATION:
PuriCore plc Tel: +1 (484) 321 2701
Greg Bosch, Chief Executive Officer
Keith A. Goldan, Chief Financial Officer
Financial Dynamics Tel: +44 (0) 20 7831 3113
Ben Brewerton
John Gilbert
ABOUT PURICORE PLC
PuriCore is a life sciences company focused on the development and
commercialisation of its proprietary technology that mimics the
production by the human body of its natural anti-microbial, hypochlorous
acid. Hypochlorous acid is highly effective at killing pathogens such as
bacteria, viruses and fungi and yet is safe and environmentally
friendly. PuriCore's solutions have applications in a wide range of
markets where it is important to control microbial contamination. These
markets include medical device disinfection, food safety, dental
equipment decontamination, environmental remediation, hospitality, water
safety, wound management and other applications intended to limit the
spread of infectious disease, including major global disease threats such
as Tuberculosis, MRSA, Influenza, E.coli, Norovirus, HIV, polio, Hepatitis
A, H.pylori and Legionella.
PuriCore markets a portfolio of branded systems which produce
hypochlorous acid solutions on-site at a customer's location from water,
electricity and common salt. These solutions are generated at a range of
concentrations and at a nearly neutral pH range similar to the human
body. They are effective as soaks, sprays, mists and in other forms.
PuriCore is headquartered in Malvern, Pennsylvania and has offices in
Stafford, UK.
To receive additional information on the Company, please visit our Web
site at
www.puricore.com, which does not form part of this press release.
This information is provided by RNS
The company news service from the London Stock Exchange